Literature DB >> 8074475

Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists.

M Abdul1, P E Anezinis, C J Logothetis, N M Hoosein.   

Abstract

Neuroendocrine (NE) differentiation within the primary prostate tumor has been correlated with tumor progression and shortened patient survival. Serotonin (5-hydroxytryptamine, 5-HT), a known mitogen, is found in most neuroendocrine cells of the human prostate. We have previously found that human prostatic carcinoma cell lines, PC-3, DU-145 and LNCaP, display certain NE characteristics. In this study, we have examined the effects of several subtype-selective 5-HT receptor antagonists on the growth of the three lines. Of these, the 5-HT1A antagonist pindobind had the most marked antiproliferative effect in vitro. Pindobind also had marked growth-inhibitory effects on the aggressive PC-3 cell line in vivo, in athymic nude mice. Radioligand binding studies indicated the presence of 5-HT binding sites on all three cell lines. Our results suggest that 5-HT is involved in the growth of prostate tumor cells and may serve as a target for treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074475

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

2.  Pharmacology of cloned human 5-HT1D receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT1D and 5-HT1B receptors.

Authors:  P J Pauwels; C Palmier; T Wurch; F C Colpaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

3.  Androgen-repressed phenotype in human prostate cancer.

Authors:  H Y Zhau; S M Chang; B Q Chen; Y Wang; H Zhang; C Kao; Q A Sang; S J Pathak; L W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 4.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

5.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

6.  Effects of nefazodone on the development of experimentally induced tumors in stressed rodents.

Authors:  Manuel Freire-Garabal; Manuel Rey-Méndez; Luis A García-Vallejo; José Balboa; José M Suárez; Elena Rodrigo; Julio Brenlla; María J Núñez
Journal:  Psychopharmacology (Berl)       Date:  2004-05-26       Impact factor: 4.530

7.  5-HT7 receptors as a new target for prostate cancer physiopathology and treatment: an experimental study on PC-3 cells and FFPE tissues.

Authors:  Irfan Cinar; Busra Sirin; Zekai Halici; Saziye Sezin Palabiyik-Yucelik; Erol Akpinar; Elif Cadirci
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-02       Impact factor: 3.000

8.  An indicator of cancer: downregulation of monoamine oxidase-A in multiple organs and species.

Authors:  Leszek A Rybaczyk; Meredith J Bashaw; Dorothy R Pathak; Kun Huang
Journal:  BMC Genomics       Date:  2008-03-20       Impact factor: 3.969

9.  The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.

Authors:  Mark P Labrecque; Mandeep K Takhar; Rebecca Nason; Stephanie Santacruz; Kevin J Tam; Shabnam Massah; Anne Haegert; Robert H Bell; Manuel Altamirano-Dimas; Colin C Collins; Frank J S Lee; Gratien G Prefontaine; Michael E Cox; Timothy V Beischlag
Journal:  Oncotarget       Date:  2016-04-26

10.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.

Authors:  M E Harper; E Glynne-Jones; L Goddard; V J Thurston; K Griffiths
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.